Denifanstat

Sagimet Biosciences' stock surged 30% due to clinical successes, regulatory endorsements, and positive analyst sentiment. Their lead candidate, Denifanstat, received FDA Breakthrough Therapy designation for MASH, showing potential to improve liver health metrics and fibrosis. The company faces challenges like funding for Phase 3 trials and limited market capitalization.

TD Cowen analyst Ritu Baral initiates Buy rating on Sagimet Biosciences, Inc. (SGMT) due to strategic advancements, including two Phase 3 trials (FASCINATE-3 and FASCINIT) for non-cirrhotic MASH treatment, and strong financial position with $170 million in cash. UBS also initiates Buy rating with $12.00 price target.

Sagimet Biosciences reports financial results for Q3 2024, highlighting the FDA's Breakthrough Therapy designation for denifanstat in MASH and the successful completion of end-of-Phase 2 interactions, paving the way for a Phase 3 program expected by end of 2024. The company anticipates a cash runway through 2025 with $170.0 million in cash, cash equivalents, and marketable securities as of September 30, 2024.

Sagimet Biosciences Inc. reports no license revenue, a $(16.9) million loss from operations, and a $(14.6) million net loss in its latest Form 10-Q. The company is advancing denifanstat, a FASN inhibitor, into Phase 3 trials for MASH, with FDA Breakthrough Therapy designation. Sagimet plans to initiate two Phase 3 trials by end of 2024 and expand its pipeline into acne and cancer. The company faces operational, liquidity, and regulatory risks, relying on external funding and third-party vendors.

Sagimet Biosciences reported Q3 2024 financial results and updates, including FDA's Breakthrough Therapy designation for denifanstat in MASH treatment, publication of Phase 2b FASCINATE-2 study results in The Lancet, and successful end-of-Phase 2 FDA interactions. The company plans to initiate Phase 3 program by end of 2024, with $170.0 million in cash and equivalents as of September 30, 2024, and a Q3 net loss of $14.6 million.

The article discusses the importance of enabling JavaScript for optimal app performance.